Advertisement

Pulmonary Actions of the Endothelins

  • Roy G. Goldie
  • Douglas W. P. Hay

Part of the Respiratory Pharmacology and Pharmacotherapy book series (RPP)

Table of contents

  1. Front Matter
    Pages i-x
  2. Katsutoshi Goto
    Pages 1-20
  3. Timothy D. Warner
    Pages 21-48
  4. Nicholas W. Morrell, Carlos Orte, John Wharton, Julia M. Polak
    Pages 49-62
  5. Pedro D’Orléans-Juste, Jean-Philippe Gratton, Ghassan Bkaily, Adel Giaid
    Pages 63-82
  6. Claude Bertrand, Emmanuel Naline, Charles Advenier
    Pages 107-123
  7. William M. Abraham
    Pages 125-141
  8. Vera P. Krymskaya, Reynold A. Panettieri Jr
    Pages 143-154
  9. Joaquim Mullol, James N. Baraniuk, Cesar Picado, James H. Shelhamer
    Pages 155-176
  10. János G. Filep, Douglas W. P. Hay
    Pages 177-196
  11. Karen O. McKay
    Pages 197-211
  12. Bernadette Raffestin, Saadia Eddahibi, Serge Adnot
    Pages 213-230
  13. Back Matter
    Pages 265-270

About this book

Introduction

The biology of the family of endogenous autocrine peptides known as the endothelins (ETs) has been a source of intense study for researchers since 1988, following the identification of ET-l as the previously described endothelium-derived contractile factor. Initial interest focussed on the actions of the ETs in the cardiovascular system, and this remains the pri­ mary source of published work involving these peptides. Importantly, evi­ dence is mounting for a significant mediator role for ET-l in cardiovascu­ lar diseases including systemic hypertension and congestive heart failure. However, it was also recognized early on that the ETs exert an array of powerful actions in the respiratory tract, many of which prompted specula­ tion concerning mediator roles for ET-l in several lung diseases including asthma and pulmonary hypertension. In recent years the evidence for the involvement of ET-l in lung diseases has become more compelling. There is now real hope and anticipation that novel ET receptor antagonists may eventually be used therapeutically against asthma and other major lung pathologies. It is this atmosphere of excitement created by new discoveries and the increasing scientific ratio­ nale for a significant impact ofthe ETs in pulmonary diseases that prompt­ ed the creation of this book, the first on this topic. Most of the information presented relates to ET-l, which is the most widely studied member of the ET family.

Keywords

asthma biology clinical research development diseases endothelium enzymes growth research signal transduction smooth muscle tissue

Editors and affiliations

  • Roy G. Goldie
    • 1
  • Douglas W. P. Hay
    • 2
  1. 1.Faculty of Medicine & Dentistry Department of PharmacologyUniversity of Western AustraliaPerth NedlandsAustralia
  2. 2.Department of Pulmonary PharmacologySmithKline Beecham PharmaceuticalsKing of PrussiaUSA

Bibliographic information

Industry Sectors
Pharma
Health & Hospitals
Biotechnology